版本:
中国

BRIEF-Galenica says FDA approves supplemental new drug application for Veltassa

Nov 28 Galenica AG :

* FDA approves supplemental new drug application (SNDA) for Veltassa removing boxed warning regarding drug-drug interactions01

* Approval reinforces potential of Veltassa as a key platform of additional growth for Vifor Pharma

* Vifor Pharma to make necessary investments to achieve veltassa's significant mid-term potential

* Relypsa, Inc., a Vifor Pharma company, has received approval from FDA for a SNDA with important updates to us label of Veltassa (patiromer) for oral suspension Source text - bit.ly/2gxx1jR Further company coverage: (Gdynia Newsroom)

更多 瑞士市场报道

热门文章

编辑推荐

文章推荐